The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced last year. A phase 1b trial ...

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...

Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an ...

The companies plan to create a treatment combining Roche’s GLP-1 asset, CT-388, with Zealand Pharma’s amylin analog.

as well as a fixed-dose combination with Roche's lead incretin asset CT-388. Get top local stories in Connecticut delivered to you every morning. Sign up for NBC Connecticut's News Headlines ...

Roche and Zealand Pharma have entered into a partnership worth up to $5.3bn to advance Zealand’s mid-stage obesity candidate petrelintide.

Why it matters: Roche entered the obesity landscape with the $2.7 billion acquisition of Carmot in early 2024, giving the firm access to development-stage candidates, including CT-388 and oral ...

Roche Holding agreed a collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment using its CT-388 medicine combined with Zealand Pharma's petrelintide. The Swiss ...